Original Research
Published on 20 Jun 2023
CL-705G: a novel chemical Kir6.2-specific KATP channel opener
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1197257
- 2,804 views
Type at least 3 characters
3,256 articles
Articles
Original Research
Published on 19 Jun 2023
Phosphoproteomic and proteomic profiling in post-infarction chronic heart failure
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1181622
- 2,634 views
- 3 citations
Original Research
Published on 16 Jun 2023
Induction of RIPK3/MLKL-mediated necroptosis by Erigeron breviscapus injection exhibits potent antitumor effect
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1219362
- 3,768 views
- 4 citations
Original Research
Published on 16 Jun 2023
Design, in silico and pharmacological evaluation of a peptide inhibitor of BACE-1
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1184006
- 3,426 views
- 3 citations
Original Research
Published on 15 Jun 2023
A new cirrhotic animal protocol combining carbon tetrachloride with methotrexate to address limitations of the currently used chemical-induced models
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1201583
- 2,990 views
Original Research
Published on 15 Jun 2023
Licraside as novel potent FXR agonist for relieving cholestasis: structure-based drug discovery and biological evaluation studies
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1197856
- 1,940 views
- 2 citations
Editorial
Published on 15 Jun 2023
Editorial: Opioids and opioid-use disorders
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1227174
- 1,328 views
- 1 citation
Original Research
Published on 15 Jun 2023
Tetrandrine inhibits the proliferation of mesangial cells induced by enzymatically deglycosylated human IgA1 via IgA receptor/MAPK/NF-κB signaling pathway
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1150829
- 2,263 views
- 1 citation
Original Research
Published on 15 Jun 2023
Cell-free supernatant of probiotic bacteria exerted antibiofilm and antibacterial activities against Pseudomonas aeruginosa: A novel biotic therapy
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1152588
- 8,381 views
- 8 citations
Review
Published on 12 Jun 2023
Amphibian-derived wound healing peptides: chemical molecular treasure trove for skin wound treatment
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1120228
- 3,486 views
- 12 citations
Systematic Review
Published on 12 Jun 2023
Anti-vascular endothelial growth factor monotherapy or combined with verteporfin photodynamic therapy for retinal angiomatous proliferation: a systematic review with meta-analysis
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1141077
- 1,770 views
- 1 citation
Original Research
Published on 09 Jun 2023
Exploring the potential mechanisms of Shiwei Hezi pill against nephritis based on the method of network pharmacology
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1178734
- 2,081 views
- 2 citations
Review
Published on 07 Jun 2023
Bryostatin-1: a promising compound for neurological disorders
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1187411
- 6,799 views
- 9 citations
Original Research
Published on 06 Jun 2023
Luteolin inhibits triple-negative breast cancer by inducing apoptosis and autophagy through SGK1-FOXO3a-BNIP3 signaling
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1200843
- 4,884 views
- 13 citations
Correction
Published on 02 Jun 2023
Corrigendum: Diclofenac and other non-steroidal anti-inflammatory drugs (NSAIDs) are competitive antagonists of the human P2X3 receptor
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1225522
- 1,040 views
Original Research
Published on 01 Jun 2023
Arum palaestinum delays hepatocellular carcinoma proliferation through the PI3K-AKT-mTOR signaling pathway and exhibits anticoagulant effects with antimicrobial properties
in Experimental Pharmacology and Drug Discovery
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1180262
- 2,519 views
- 1 citation